Ozempic

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Summary

What it does
Ozempic (Semaglutide) cuts body weight by 15 to 21 percent in trials and improves blood-sugar control. It also lowers the risk of heart attack and stroke by about 20 percent. Nausea is common.
How it works
A weekly injection, or a daily pill, that copies GLP-1, a gut hormone released after a meal. It tells the brain that the body is full and slows the stomach, so hunger falls.
WADA status
Permitted under World Anti-Doping Agency (WADA) rules. Drug-tested athletes can use it.

Ozempic (Semaglutide; also known as GLP-1 agonist) is a modified peptide studied for its effects on fat loss, weight loss, and cardiovascular health. FDA-approved GLP-1 agonist (Ozempic/Wegovy/Rybelsus) with 15-21% weight loss and 20% cardiovascular risk reduction. Nausea common, NAION risk noted.

Semaglutide is an FDA-approved GLP-1 receptor agonist with 94% structural homology to human GLP-1, manufactured by Novo Nordisk as Ozempic (diabetes, 0.25-2mg weekly injection), Wegovy (obesity, up to 2.4mg weekly injection), and Rybelsus (diabetes, 3-14mg daily oral). Activates GLP-1 receptors in the gastrointestinal tract, pancreas, and brain to reduce appetite, delay gastric emptying, increase insulin release, and lower glucagon secretion. STEP trials demonstrated 14.9-17.4% mean weight loss at 68 weeks (2.4mg dose), with 69-79% achieving ≥10% weight loss.

Natty status
Ozempic is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Dosage and administration
  5. 5 Natty status
  6. 6 Research
  7. 7 Related compounds
  8. 8 Frequently asked questions
  9. 9 References
  10. 10 External links

Overview

STEP UP trial showed 20.7% weight loss with 7.2mg dose at 72 weeks.

SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiac events (HR 0.80) in patients with obesity and preexisting cardiovascular disease but without diabetes.

FDA-approved March 2024 for reducing cardiovascular death, heart attack, and stroke risk.

Also approved for metabolic-associated steatohepatitis (MASH).

Most common side effects are gastrointestinal (nausea affecting up to 20%, vomiting, diarrhea, constipation), typically transient and mild-to-moderate.

Notable concerns include possible gastroparesis, 85% increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), and thyroid cancer warnings from rodent studies (though human incidence <1%).

Available in both injection (89% bioavailability) and oral forms (0.4-1% bioavailability).

Gradual titration over 12-16 weeks minimizes gastrointestinal side effects.

Mechanism of action

Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.

Reported effects

Effects reported in the literature and from preclinical models include:

  • Semaglutide is FDA-approved for long-term obesity management, and once-daily oral semaglutide produced greater weight loss than placebo in the OASIS 1, 2 and 4 trials. [9][6] FDA approved
  • In a network meta-analysis of randomized trials in adults with overweight or obesity without diabetes, subcutaneous semaglutide 2.4 mg reduced body weight by about 11.45% more than placebo. [3] Phase II
  • Semaglutide is FDA-approved for metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis. [4][2] FDA approved
  • In placebo-controlled randomized trials, semaglutide reduced liver enzymes and more than doubled the likelihood of steatohepatitis resolution without fibrosis progression, though improvement in fibrosis stage alone was not statistically significant. [7] Phase II
  • Across four SUSTAIN randomized controlled trials in type 2 diabetes uncontrolled on oral drugs, once-weekly semaglutide 1.0 mg lowered HbA1c by about 0.64 percentage points and body weight by 4.38 kg versus other injectable therapies, with lower hypoglycemia risk than basal insulin. [8] Phase II
  • Large observational cohort studies associated semaglutide and other GLP-1 receptor agonists with a higher risk of non-arteritic anterior ischemic optic neuropathy in type 2 diabetes, with a pooled hazard ratio of about 3.36 at one year for semaglutide, though absolute incidence rates remained small. [5][1] Phase I

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

⚠
Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

Injectable

  • Week 1-4: 0.25mg once weekly (subcutaneous)
  • Week 5-8: 0.5mg once weekly
  • Week 9-12: 1.0mg once weekly
  • Week 13+: 2.0mg (Ozempic) or 2.4mg (Wegovy) maximum
  • Higher dose: 7.2mg weekly (experimental, 20.7% weight loss)

Oral Rybelsus

  • Days 1-30: 3mg daily on empty stomach
  • Days 31-60: 7mg daily
  • Day 61+: 14mg daily maximum

General

  • Take oral form with ≤4oz water, wait 30 min before eating
  • Gradual titration over 12-16 weeks reduces GI side effects

Natty status

See also: Peptide § Natty status

Ozempic is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[10]

Research

244 active clinical trials on record — highest phase: Phase 4. 797 registered in total , of which 357 completed
View on ClinicalTrials.gov · fetched Oct 5, 2026

The peptide has been the subject of 67 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Tirzepatide Natty
Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.
Retatrutide Not natty
Triple agonist that curbs appetite and raises energy expenditure for 24% weight loss. Improves blood sugar, lowers blood pressure, and normalizes liver fat. Investigational; not FDA-approved.
5-Amino-1MQ Not natty
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.
MOTS-c Not natty
Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.

Frequently asked questions

What is Ozempic?

FDA-approved GLP-1 agonist (Ozempic/Wegovy/Rybelsus) with 15-21% weight loss and 20% cardiovascular risk reduction. Nausea common, NAION risk noted.

What is Ozempic used for?

Ozempic (Semaglutide) cuts body weight by 15 to 21 percent in trials and improves blood-sugar control. It also lowers the risk of heart attack and stroke by about 20 percent. Nausea is common.

How does Ozempic work?

A weekly injection, or a daily pill, that copies GLP-1, a gut hormone released after a meal. It tells the brain that the body is full and slows the stomach, so hunger falls.

Is Ozempic natty?

Ozempic is generally regarded as compatible with natural bodybuilding. Most sanctioning bodies do not prohibit its therapeutic use, though rules vary by federation.

Is Ozempic banned by WADA?

No. Ozempic is permitted under World Anti-Doping Agency (WADA) rules. Intravenous infusion above the volume limit of WADA method M2.2 is restricted whatever is infused, and the list is revised every year, so check the current edition before competing.

How is Ozempic administered?

Ozempic is typically administered via: subcutaneous injection, oral. Dosage and administration protocols vary; see the Dosage section for details.

References

  1. ^ NAION vision risk study
  2. ^ MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.
  3. ^ Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Recent review
  4. ^ Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. Recent review
  5. ^ Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. Recent review
  6. ^ A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. Recent review
  7. ^ Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. Recent review
  8. ^ Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis. Recent review
  9. ^ Pharmacological management of obesity: Current landscape and emerging therapies. Recent review
  10. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Fat loss | Weight loss | Cardiovascular | Diabetes

This page was last updated on October 5, 2026, at 07:28 (UTC).

Research last reviewed on October 5, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.